Kaufman D S, Shipley W U, Griffin P P, Heney N M, Althausen A F, Efird J T
Department of Medical Oncology, Massachusetts General Hospital, Boston 02114.
N Engl J Med. 1993 Nov 4;329(19):1377-82. doi: 10.1056/NEJM199311043291903.
For patients with invasive bladder cancer the usual recommended treatment is radical cystectomy, although transurethral resection of the tumor, systemic chemotherapy, and radiotherapy are each effective in some patients. We sought to determine whether these treatments in combination might be as effective as radical cystectomy and thus might allow the bladder to be preserved and the cancer cured.
We enrolled 53 consecutive patients with muscle-invading bladder cancer (stages T2 through T4, NXM0) in a trial of transurethral surgery, combination chemotherapy, and irradiation (4000 cGy) with concurrent cisplatin administration. Urologic evaluation of the tumor response directed further therapy: radical cystectomy in the 8 patients who had incomplete responses, additional chemotherapy and radiotherapy (6480 cGy) in the 34 patients who had complete responses or who were unsuited for cystectomy, and alternative care in the 11 patients who could not tolerate either irradiation or chemotherapy.
After a median follow-up of 48 months, 24 of the 53 patients (45 percent) were alive and free of detectable tumor. In 31 patients (58 percent) the bladder was free of invasive tumor and functioning well, even though in 9 (17 percent) a superficial tumor recurred and required further transurethral surgery and intravesical drug therapy. Of the 28 patients who had complete responses after initial treatment, 89 percent had functioning tumor-free bladders.
Conservative combination treatment may be an acceptable alternative to immediate cystectomy in selected patients with bladder cancer, although a randomized clinical trial that included a group for simultaneous comparison would be required to produce definitive results.
对于浸润性膀胱癌患者,通常推荐的治疗方法是根治性膀胱切除术,尽管经尿道肿瘤切除术、全身化疗和放疗对部分患者也有效。我们试图确定这些治疗方法联合使用是否与根治性膀胱切除术同样有效,从而有可能保留膀胱并治愈癌症。
我们连续纳入了53例肌层浸润性膀胱癌患者(T2至T4期,NXM0),进行经尿道手术、联合化疗和放疗(4000厘戈瑞)并同时给予顺铂的试验。对肿瘤反应进行泌尿外科评估以指导进一步治疗:对8例反应不完全的患者行根治性膀胱切除术,对34例反应完全或不适合行膀胱切除术的患者追加化疗和放疗(6480厘戈瑞),对11例无法耐受放疗或化疗的患者给予其他治疗。
中位随访48个月后,53例患者中有24例(45%)存活且未检测到肿瘤。31例患者(58%)膀胱无浸润性肿瘤且功能良好,尽管其中9例(17%)出现浅表肿瘤复发,需要进一步经尿道手术和膀胱内药物治疗。在初始治疗后反应完全的28例患者中,89%的患者膀胱功能正常且无肿瘤。
对于部分膀胱癌患者,保守联合治疗可能是立即行膀胱切除术的可接受替代方案,尽管需要进行包括同期比较组的随机临床试验才能得出确切结果。